Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.84 |
| ▸ | THRB | P10828 | 10/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.84 |
| ▸ | BLM | P54132 | 9/20 | 0.84 |
| ▸ | RECQL | P46063 | 8/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.84 |
| ▸ | MAPT | P10636 | 7/20 | 0.84 |
| ▸ | BRCA1 | P38398 | 7/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.84 |
| ▸ | TOP2A | P11388 | 5/20 | 0.84 |
| ▸ | HTT | P42858 | 5/20 | 0.84 |
| ▸ | STAT6 | P42226 | 5/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.84 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10119585 | 1.00 | MEN1 (0.84) | MEN1THRBKMT2ABLMRECQL | |
| SCHEMBL9889374 | 1.00 | MEN1 (0.84) | MEN1THRBKMT2ABLMRECQL | |
| SCHEMBL10061864 | 1.00 | MEN1 (0.84) | MEN1THRBKMT2ABLMRECQL | |
| SCHEMBL9942593 | 1.00 | MEN1 (0.84) | MEN1THRBKMT2ABLMRECQL | |
| SCHEMBL10061915 | 1.00 | MEN1 (0.84) | MEN1THRBKMT2ABLMRECQL | |
| SCHEMBL9607868 | 1.00 | MEN1 (0.84) | MEN1THRBKMT2ABLMRECQL | |
| SCHEMBL15890537 | 1.00 | MEN1 (0.84) | MEN1THRBKMT2ABLMRECQL | |
| SCHEMBL17752025 | 1.00 | MEN1 (0.84) | MEN1THRBKMT2ABLMRECQL | |
| SCHEMBL9607869 | 1.00 | MEN1 (0.84) | MEN1THRBKMT2ABLMRECQL | |
| SCHEMBL9889375 | 1.00 | MEN1 (0.84) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8470297-B1 | FDG-pet evaluation of Ewing's sarcoma sensitivity | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120244193-A1 | PASSIVE SOLID TUMOR TARGETING ANTICANCER PRODRUG AND PREPARATION METHOD THEREOF | CHONGQING LUMMY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-27 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
| US-20110014117-A1 | ANTI-IGF1R | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| US-20100240594-A1 | TARGETED DELIVERY OF CHEMOTHERAPEUTIC AGENTS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-09-23 | — | — | US | disclosed |
| US-7754874-B2 | Have significantly enhanced cytotoxic potency toward human cancer cells and tumor-specificity, are less potent Na+/K+-ATPase inhibitors in a human cell line than digitoxin | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | IGF1R, IRS1, EWSR1 | MEN1 452/4885THRB 281/4885KMT2A 2105/4885 |
| US-20120244193-A1 | PASSIVE SOLID TUMOR TARGETING ANTICANCER PRODRUG AND PREPARATION METHOD THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, H1-4 | MEN1 2980/4885THRB 4766/4885KMT2A 1121/4885 |
| US-20110014117-A1 | ANTI-IGF1R | IGF1R, IGFBP1, IGFBP2 | MEN1 780/4885THRB 51/4885KMT2A 3952/4885 |
| US-20120058112-A1 | ANTIBODIES | IGF1R, EGFR, ERBB3 | MEN1 609/4885THRB 431/4885KMT2A 576/4885 |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | TERF2IP, TERF2, DOT1L | MEN1 373/4885THRB 1144/4885KMT2A 39/4885 |
| US-20110262525-A1 | METHODS OF TREATMENT | ASAH2, FOLH1, CD44 | MEN1 1217/4885THRB 3050/4885KMT2A 2834/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | MEN1 552/4885THRB 76/4885KMT2A 2771/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | MEN1 1251/4885THRB 4593/4885KMT2A 2332/4885 |
| US-20100240594-A1 | TARGETED DELIVERY OF CHEMOTHERAPEUTIC AGENTS | TP53, TOP2A, MCL1 | MEN1 1871/4885THRB 4508/4885KMT2A 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.